[FB]
The New Migraine Drugs: Expensive and Less Effective Than Nutritional Therapy
By Alan R. Gaby, MD
You may have noticed the recent ad blitz for Aimovig (erenumab), a new drug for migraine prevention that was approved by the US Food and Drug Administration (FDA) in May 2018. A new TV commercial depicts emotional scenes such as hugging a child, gazing in awe at the stars, and tearfully embracing one’s significant-other, as the voice in the background declares, “The awe-inspiring. The heart-racing. The heartbreaking. That’s what life is all about – showing up. Unless migraine steals your chance to say, ‘I am here.’” In launching this new ad campaign, Amgen and Novartis (which jointly market Aimovig) are hoping to gain a competitive advantage over two similar drugs that achieved FDA approval four months later: Ajovy (fremanezumab-vfrm; Teva Pharmaceuticals) and Emgality (galcanezumab; Eli Lilly).
Each of these newly approved migraine drugs functions as a calcitonin gene-related peptide (CGRP) antagonist by binding to the peptide itself or to its receptor. CGRP is a 37-amino acid neuropeptide produced in the peripheral and central nervous system that has been shown to play a role in the pathogenesis of migraine. All three drugs are administered once a month by injection. And surprisingly (or perhaps not surprisingly), all three drugs carry the identical price tag of $575 per dose, or $6,900 per year. That price is well beyond the budget of the average person. Therefore, each of the drug companies is offering a program where patients with insurance can receive the drug for little or no out-of-pocket cost for up to 12 months, while the companies continue their negotiations with insurers over prices. Those tactics seem eerily reminiscent of a street dealer handing out free samples in order to get his clientele hooked on his drug.
So, what benefit could a migraine sufferer expect to obtain from taking one of these $6,900-per-year drugs? In several industry-sponsored randomized controlled trials, the improvements were modest or, at best, moderate. In a double-blind trial published in the New England Journal of Medicine, 43.3% of patients receiving erenumab, as compared with 26.6% of those receiving placebo, achieved at least a 50% reduction in the number of migraine days per month.1 This absolute difference in response rate of 16.6% means that for every six patients treated with the drug, only one would achieve at least a 50% decrease in migraine days (i.e., the number-needed-to-treat is 6). In a similar trial, 39.7% of patients receiving erenumab, as compared with 29.5% of those receiving placebo, achieved at least a 50% reduction in the number of migraine days per month.2 This absolute difference of 10.2% corresponds to a number-needed-to-treat of 10. Similar results were seen in clinical trials of fremanezumab-vfrm and galcanezumab.
Comparison with Low-Cost Nutritional Therapies
How do those results compare with the results of evidenced-based, but underutilized natural approaches to migraine prophylaxis? In a double-blind trial, 59% of patients receiving 400 mg per day of riboflavin, as compared with 15% of those given placebo, had at least a 50% decrease in the number of migraine days (p = 0.002).3 This absolute difference of 44% corresponds to a number-needed-to-treat of only 2.3. The retail cost of a year’s supply of riboflavin is approximately $40.
In another double-blind trial, migraine patients received 100 mg of coenzyme Q10 (CoQ10) three times per day or placebo for four months. The proportion of patients who had a 50%-or-greater reduction in attack frequency in month four compared with baseline was 47.6% with CoQ10 and 14.3% with placebo (p = 0.02), corresponding to a number-needed-to-treat of 3.0.4 The price (and apparently the quality) of CoQ10 varies among different commercial products, but a year’s supply of high-quality CoQ10 at the dosage used in this study can be obtained for less than $500 per year.
Oral magnesium supplementation has also been shown to reduce migraine recurrences, although not all studies have been positive.5 Comparisons with the abovementioned trials are difficult, because the data were not reported as the proportion of patients who experienced at least a 50% reduction in headache frequency. In clinical practice, however, I have seen many migraine patients who reported positive experiences with magnesium supplementation. A year’s supply of magnesium (at a daily dose of 400 mg) can cost as little as $30.
For migraine sufferers willing to take on the sometimes arduous task of identifying and avoiding hidden food allergens, the results can be even more pronounced than those achievable with any of the pharmaceutical or nutritional treatments discussed above. In one clinical trial, 60 patients with a long history of recurrent migraines underwent an elimination diet followed by individual food challenges. On average, patients discovered reactions to 10 different foods. When the symptom-evoking foods were removed from the diet, the mean number of migraines in the group as a whole fell by 98%, and 85% of the patients became headache-free.6
Modern Medicine’s “Wrong Turn”
Thus, we have another example of how the pharmaceutical industry spends hundreds of millions of dollars to obtain monopolies on drugs that can then extract billions of additional dollars from a healthcare system on the brink of financial collapse. These overpriced drugs do not necessarily work better than low-cost alternatives that are already available. In the case of migraines, the new drugs appear to be less effective than some dietary interventions and nutritional supplements, and may also be no more effective than some of the older drugs used for migraine prophylaxis.
The ongoing political debate regarding healthcare in the United States centers primarily on how it should be paid for. Not enough attention is given to the reasons it is so expensive and how we might lower the cost. Two simple changes could make healthcare much more affordable. First, insurance companies should agree to pay for evidence-based low-cost natural remedies, even if they have not been officially “approved” by the FDA. Second, the FDA should stop prohibiting distributers of nutritional supplements and herbs from truthfully disseminating scientific evidence that supports the efficacy of their products. If people were armed with the facts, and if insurance companies were to cover various low-cost evidence-based natural remedies, I believe there would be a serious change in the market for overpriced, marginally beneficial, and potentially toxic medications.
-
References
. Goadsby PJ, et al. A controlled trial of erenumab for episodic migraine. N Engl J Med. 2017;377:2123-2132.↩︎
-
. Dodick DW, et al. ARISE: A Phase 3 randomized trial of erenumab for episodic migraine. Cephalalgia. 2018;38:1026-1037.↩︎
-
. Schoenen J, et al. Effectiveness of high-dose riboflavin in migraine prophylaxis. A randomized controlled trial. Neurology. 1998;50:466-470.↩︎
-
. Sandor PS, et al. Efficacy of coenzyme Q10 in migraine prophylaxis: a randomized controlled trial. Neurology. 2005;64:713-715.↩︎
-
. Gaby AR. Migraine. In Gaby AR. Nutritional Medicine, Second Edition. Concord, NH, 2017, www.doctorgaby.com, chapter 136.↩︎
-
. Grant EC. Food allergies and migraine. Lancet. 1979;1:966-969.↩︎









0 Comments